COMPASS Pathways (CMPS) is trading down at $8.05 (-6.94%) on NASDAQ, as of the latest quote. It operates in the Health Care sector.
One firm's current price target on COMPASS Pathways: $21 — 161% above the current $8.05. Each is tracked to its date and scored the same way a member's call is.
1 target, newest first. Open a row for its source and scoring.
Entry price $8.59, the close nearest Nov 3, 2026, when the target was reported; the target is +144% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.
Scoring Open: judged on the close on Nov 3, 2027.
Investing.com - Stifel maintained its Buy rating and $21.00 price target on Compass Pathways stock (NASDAQ:CMPS), citing strong execution as the company finalizes its regulatory submission.
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Operating income | −$21.2M | −$51.4M | −$83.2M | −$110.4M | −$136.9M | −$178.2M | −$179.0M |
| Net income | −$19.6M | −$60.3M | −$71.7M | −$91.5M | −$118.5M | −$155.1M | −$287.9M |
| EPS (diluted) | −$2.62 | −$3.55 | −$1.79 | −$2.16 | −$2.32 | −$2.30 | −$3.08 |
| Balance sheet | |||||||
| Cash and equivalents | $25.0M | $190.3M | $273.2M | $143.2M | $220.2M | $165.1M | $149.6M |
| Total assets | $32.4M | $203.5M | $300.9M | $197.3M | $276.0M | $213.7M | $210.3M |
| Total liabilities | $23.9M | $6.89M | $16.5M | $16.0M | $50.2M | $59.0M | $263.2M |
| Long-term debt | — | — | — | $0 | $28.8M | $24.7M | $14.1M |
| Shareholders' equity | −$30.4M | $196.6M | $284.4M | $181.3M | $225.7M | $154.7M | −$52.8M |
| Cash flow | |||||||
| Operating cash flow | −$17.8M | −$41.4M | −$67.7M | −$105.5M | −$97.4M | −$119.2M | −$157.2M |
| Capital expenditure | $165.0K | $131.0K | $334.0K | $596.0K | $66.0K | $0 | — |
| Free cash flow | −$18.0M | −$41.5M | −$68.1M | −$106.0M | −$97.4M | −$119.2M | — |
| Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | Q3 FY26Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$48.4M | −$49.6M | −$42.9M | −$40.5M | −$46.0M | −$42.9M | −$52.4M | −$56.4M |
| Net income | −$43.3M | −$17.9M | −$38.4M | −$137.7M | −$93.9M | $91.2M | −$253.8M | −$9.83M |
| EPS (diluted) | −$0.63 | −$0.24 | −$0.41 | −$1.44 | −$0.99 | −$0.30 | −$1.88 | −$0.31 |
| Balance sheet | ||||||||
| Cash and equivalents | $165.1M | $260.1M | $221.9M | $185.9M | $149.6M | $466.0M | $433.3M | $444.0M |
| Total assets | $213.7M | $319.1M | $293.5M | $255.6M | $210.3M | $531.7M | $504.6M | $519.1M |
| Total liabilities | $59.0M | $123.7M | $131.0M | $218.0M | $263.2M | $205.1M | $420.0M | $377.0M |
| Long-term debt | $24.7M | $21.6M | $23.0M | $18.6M | $14.1M | $50.5M | $50.7M | $49.6M |
| Shareholders' equity | $154.7M | $195.5M | $162.6M | $37.6M | −$52.8M | $326.7M | $84.5M | $142.1M |
| Cash flow | ||||||||
| Operating cash flow | −$41.8M | −$45.7M | −$38.7M | −$35.1M | −$37.8M | −$47.9M | −$40.3M | −$50.8M |
| Capital expenditure | $0 | — | — | — | — | — | — | — |
| Free cash flow | −$41.8M | — | — | — | — | — | — | — |
From COMPASS Pathways's 10-K, 10-Q, 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Read at Investing.com ↗ Link to this story
Read at Stocktwits ↗ Link to this story
Also mentions Advanced Micro Devices, SpaceX, Alphabet Inc. (Class A), Intellia Therapeutics Inc, Crispr Therapeutics AG
Read at TradingView ↗ Link to this story
Also mentions Advanced Micro Devices, SpaceX, Alphabet Inc. (Class A), Intellia Therapeutics Inc, Crispr Therapeutics AG
Read at Investing.com ↗ Link to this story
Also mentions Morgan Stanley
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).
Source: Wikipedia — Compass Pathways